- Company name
- BrightSpring Health Services
- Sector
- Home health care and pharmacy services
- About
- BrightSpring Health Services, Inc. (BTSG) is based in Louisville, Kentucky. It gives pharmacy and health services at home and in the community to patients with complex needs. Its Pharmacy Solutions segment includes specialty and infusion pharmacy and home and community pharmacy, and it dispensed about 10.9 million prescriptions in Q3 2026. Its Provider Services segment includes home health care, hospice, rehabilitation and personal care. In December 2025 it bought 107 home health and hospice branches from Amedisys and UnitedHealth Group, and on March 30, 2026 it sold its Community Living business for gross proceeds of $835 million. In 2025, revenue from continuing operations was $12,911 million. In Q3 2026, Pharmacy Solutions gave $3,732 million of revenue of $4,213 million. Investment funds of KKR are large shareholders and sold shares in 2026. The common stock trades on the Nasdaq in US dollars. BrightSpring files 10-K and 10-Q reports.
- Thesis
- Investors pay more than the AI estimate for BrightSpring because Adjusted EBITDA grew 42.0% in Q3 2026 and the company raised its 2026 guidance three times, to $850 million to $860 million. The growth comes mainly from specialty pharmacy, where revenue per prescription rose 24%, and from the home health branches that it bought from Amedisys and UnitedHealth Group. The price asks for this growth to continue for years. For the price to hold, three things must be true. Pharmacy margins must hold while Medicare drug price negotiation lowers the prices of some drugs. Medicare and Medicaid rates for home health and personal care must not fall. Leverage must stay below 2 times while the company buys more growth. The settlement of the tangible equity units on February 1, 2027 and the Q4 2026 report with 2027 guidance, expected in late February 2027, are the next tests. Only several years of fast profit growth can earn this price.
- Valuation
- The intrinsic value for BrightSpring Health Services is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of BrightSpring with the SEC. The method is a multiple of 2027 Adjusted EBITDA, less net debt and the redeemable noncontrolling interests, divided by the diluted share count. The Q4 2025 release (8-K, February 27, 2026) gives 2025 revenue from continuing operations of $12,911 million and Adjusted EBITDA of $618 million. The Q3 2026 release (8-K, October 30, 2026) gives Q3 revenue of $4,213 million, up 26.4%, net income from continuing operations of $101 million, Adjusted EBITDA of $228 million, up 42.0%, and 220,226 thousand diluted weighted shares for Q3. It raises 2026 guidance to revenue of $15,900 million to $16,125 million and Adjusted EBITDA of $850 million to $860 million. The Form 10-Q for the quarter ended September 30, 2026 gives total debt of $2,237.6 million, cash of $717.8 million and redeemable noncontrolling interests of $9.2 million, so the estimate takes off $1,529.0 million. It says that the purchase contracts of the tangible equity units settle on February 1, 2027 into a minimum of 26.2 million and a maximum of 30.8 million shares, and the diluted share count includes these shares. The cover of the 10-Q gives 198,984,612 shares at October 27, 2026, and the estimate uses the 220.2 million diluted shares. Adjusted EBITDA leaves out stock-based compensation and some other costs, and the estimate counts them through the multiples, which is an assumption. The 2027 Adjusted EBITDA and the multiples are assumptions. The low case assumes $880 million, because Medicare drug price rules and lower Medicare and Medicaid rates cut pharmacy and home health margins, at 10 times. It gives $33.02 per share. The base case assumes $960 million, from growth in specialty pharmacy and home health, at 14 times. It gives $54.09 per share. The high case assumes $1,040 million, from new specialty drugs and more acquisitions, at 17 times. It gives $73.34 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $53.64 per share. BrightSpring has scale in pharmacy services and home health care for patients with complex needs, but government payers set much of its prices, and other pharmacies and home health providers compete for the same patients and contracts.
As of Nov 14, 2026.
- Risks
- Government payers set much of the revenue. Home and community pharmacy revenue fell 6.3% in Q3 2026, mainly because of the Medicare drug price negotiation of the Inflation Reduction Act, and lower Medicare or Medicaid rates for home health and personal care can cut revenue and margins.
Total debt was $2,237.6 million at September 30, 2026, mostly a term loan at SOFR plus 2.00% due February 2031. Higher interest rates raise interest costs, although the company has some cash flow hedges.
Specialty pharmacy depends on access to new specialty drugs and on contracts with payers. The loss of a large drug or contract can reduce revenue.
The purchase contracts of the tangible equity units settle on February 1, 2027 into 26.2 million to 30.8 million shares, and KKR funds sold 35.0 million shares in 2026, so more share sales can come.
Acquisitions, such as the 107 Amedisys and LHC branches, can cost more or earn less than planned.
- Balance sheet
- Cash: $718M
Debt: $2.2B
Net debt: $1.5B
Net debt / EBITDA: 1.8× (low)
Undrawn credit line: $476M, to June 2028
Debt due within 12 months: $35M
Last debt due: 2031
At September 30, 2026, BrightSpring had cash of $717.8 million and total debt of $2,237.6 million, mostly the Tranche B-6 term loan due February 21, 2031. The current portion of debt was $35.3 million, including $13.0 million of amortizing notes of the tangible equity units due February 1, 2027. The revolving credit facility of $475.0 million, which matures on June 30, 2028, and the LC facility had $476.1 million available, so total liquidity was $1,194.0 million. Leverage, as the company calculates it, was 1.79 times. Total shareholders' equity was $2,176.5 million.
As of Sep 30, 2026.
- Checkpoints
- Feb 1, 2027: Settlement of the tangible equity units. Pending. Watch: The purchase contracts settle into no more than 30.8 million shares and the last amortizing note payment is made, and this passes; a delay fails.
Feb 26, 2027 (estimate): Q4 2026 results and 2027 guidance. Pending. Watch: Adjusted EBITDA for 2026 is in the range of $850 million to $860 million and the 2027 guidance shows growth, and this passes; a result below the range or flat 2027 guidance fails.
Jul 2027 (estimate): Proposed Medicare home health payment rule for 2028. Pending. Watch: The proposed rule keeps or raises home health payment rates, and this passes; a large cut fails.
- Recent events
- Oct 30, 2026: BrightSpring reported Q3 2026 revenue of $4,213 million, up 26.4%, net income from continuing operations of $101 million and Adjusted EBITDA of $228 million, up 42.0%. It raised 2026 guidance to revenue of $15,900 million to $16,125 million and Adjusted EBITDA of $850 million to $860 million.
Jul 31, 2026: BrightSpring reported Q2 2026 revenue of $3,873 million, up 23.0%, and Adjusted EBITDA of $206 million, up 44.2%, and it raised its 2026 guidance.
Jun 3, 2026: KKR funds and some managers sold 14,999,771 shares in a secondary offering, and BrightSpring bought 1,026,465 of these shares from the underwriter.
May 28, 2026: BrightSpring repaid $300.0 million of its term loan with proceeds from the Community Living sale and refinanced the remaining $2,214.9 million at SOFR plus 2.00%, down from SOFR plus 2.50%, due February 21, 2031.
May 1, 2026: BrightSpring reported Q1 2026 revenue of $3,614 million, up 25.6%, and Adjusted EBITDA of $190 million, up 44.8%, and it raised its 2026 guidance.
Mar 30, 2026: BrightSpring completed the sale of its Community Living business to National Mentor Holdings (Sevita) for gross proceeds of $835 million.
Mar 2, 2026: KKR funds and some managers sold 20,000,000 shares in a secondary offering, and BrightSpring bought 1,464,807 of these shares from the underwriter.
Feb 27, 2026: BrightSpring reported 2025 revenue from continuing operations of $12,911 million, up 28.2%, and Adjusted EBITDA of $618 million, up 34.2%.